Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?

Radiotherapy and Oncology

Volumn 86, Issue 3, 2008, Pages 428-434

  Folkvord, Sigurd ^a,b   Flatmark, Kjersti ^a,b   Seierstad, Therese ^a,c   Røe, Kathrine ^a   Rasmussen, Heidi ^a   Ree, Anne Hansen ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

5 Fluorouracil; Colorectal cancer; Oxaliplatin; Radiotherapy

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; RADIOSENSITIVITY; XENOGRAFT;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS;

EID: 40249094484     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.10.012     Document Type: Article

References (42)

1. Glimelius B., Gronberg H., Jarhult J., Wallgren A., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42 (2003) 476-492
2. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
3. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4 (2007) 86-100
4. Aschele C., Friso M.L., Pucciarelli S., et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16 (2005) 1140-1146
5. Avallone A., Delrio P., Guida C., et al. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. Br J Cancer 94 (2006) 1809-1815
6. Bountouroglou N., Ziras N., Sarris G., et al. The RACOX phase I study: radiation (RA), capecitabine (C) and oxaliplatin (OX) as adjuvant treatment of stage II and III rectal cancer. J Buon 9 (2004) 383-390
7. Fakih M.G., Rajput A., Yang G.Y., et al. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 1462-1470
8. Francois E., Ychou M., Ducreux M., et al. Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study. Eur J Cancer 41 (2005) 2861-2867
9. Freyer G., Bossard N., Romestaing P., et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 19 (2001) 2433-2438
10. Gambacorta M.A., Valentini V., Coco C., et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies. Int J Radiat Oncol Biol Phys 60 (2004) 139-148
11. Loi S., Ngan S.Y., Hicks R.J., et al. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 92 (2005) 655-661
12. Lupattelli M., Bellavita R., Natalini G., et al. Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study. Tumori 92 (2006) 474-480
13. Reerink O., Mulder N.H., Verschueren R.C., Wiggers T., Szabo B.G., and Hospers G.A. Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. Anticancer Res 25 (2005) 629-633
14. Rodel C., Grabenbauer G.G., Papadopoulos T., Hohenberger W., Schmoll H.J., and Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21 (2003) 3098-3104
15. Ryan D.P., Niedzwiecki D., Hollis D., et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: cancer and Leukemia Group B 89901. J Clin Oncol 24 (2006) 2557-2562
16. Sebag-Montefiore D., Glynne-Jones R., Falk S., Meadows H.M., and Maughan T. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 93 (2005) 993-998
17. Carraro S., Roca E.L., Cartelli C., et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 54 (2002) 397-402
18. Gerard J.P., Chapet O., Nemoz C., et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21 (2003) 1119-1124
19. Machiels J.P., Duck L., Honhon B., et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16 (2005) 1898-1905
20. Rodel C., Liersch T., Hermann R.M., et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25 (2007) 110-117
21. Turitto G., Panelli G., Frattolillo A., et al. Phase II study of neoadjuvant concurrent chemioradiotherapy with oxaliplatin-containing regimen in locally advanced rectal cancer. Front Biosci 11 (2006) 1275-1279
22. Blackstock AW, Hess S, Chaney S, Tepper JE. Oxaliplatin: in vitro evidence of its radiation sensitizing activity - pre-clinical observations relevant to clinical trials. In: Proceedings of the 41st annual ASTRO meeting, vol. 45. 1999. p. 2.
23. Espinosa M., Martinez M., Aguilar J.L., et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol 55 (2005) 301-305
24. Kjellstrom J., Kjellen E., and Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 44 (2005) 687-693
25. Koivusalo R., Krausz E., Ruotsalainen P., Helenius H., and Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62 (2002) 7364-7371
26. Magne N., Fischel J.L., Formento P., et al. Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 64 (2003) 280-287
27. Rave-Frank M., Schmidberger H., Christiansen H., Boll C., Lehmann J., and Weiss E. Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells. Int J Radiat Biol 83 (2007) 41-47
28. Cividalli A., Ceciarelli F., Livdi E., et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52 (2002) 1092-1098
29. Bleiberg H., and de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25 (1998) 32-39
30. Tankel K., Hay J., Ma R., Toy E., Larsson S., and MacFarlane J. Short-course preoperative radiation therapy for operable rectal cancer. Am J Surg 183 (2002) 509-511
31. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
32. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58 (2006) 621-681
33. Byfield J.E. 5-Fluorouracil radiation sensitization - a brief review. Invest New Drugs 7 (1989) 111-116
34. Lawrence T.S., Blackstock A.W., and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13 (2003) 13-21
35. Pawlik T.M., and Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 928-942
36. Arango D., Wilson A.J., Shi Q., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (2004) 1931-1946
37. Voland C., Bord A., Peleraux A., et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 5 (2006) 2149-2157
38. William-Faltaos S., Rouillard D., Lechat P., and Bastian G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res 26 (2006) 2093-2099
39. Xu J.M., Azzariti A., Colucci G., and Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52 (2003) 442-448
40. Das P., Lin E.H., Bhatia S., et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 66 (2006) 1378-1383
41. Yerushalmi R., Idelevich E., Dror Y., et al. Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol 93 (2006) 529-533
42. Rice J.R., Gerberich J.L., Nowotnik D.P., and Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12 (2006) 2248-2254